Directive 2020/739 - Amendment of Annex III to Directive 2000/54/EC as regards the inclusion of SARS-CoV-2 in the list of biological agents known to infect humans

Please note

This page contains a limited version of this dossier in the EU Monitor.

1.

Current status

This directive has been published on June  4, 2020, entered into force on June 24, 2020 and should have been implemented in national regulation on November 24, 2020 at the latest.

2.

Key information

official title

Commission Directive (EU) 2020/739 of 3 June 2020 amending Annex III to Directive 2000/54/EC of the European Parliament and of the Council as regards the inclusion of SARS-CoV-2 in the list of biological agents known to infect humans and amending Commission Directive (EU) 2019/1833
 
Legal instrument Directive
Number legal act Directive 2020/739
Regdoc number C(2020)3509
CELEX number i 32020L0739

3.

Key dates

Document 03-06-2020; Date of adoption
Publication in Official Journal 04-06-2020; OJ L 175 p. 11-14
Effect 24-06-2020; Entry into force Date pub. +20 See Art 4
End of validity 31-12-9999
Transposition 24-11-2020; See Art 3.1

4.

Legislative text

4.6.2020   

EN

Official Journal of the European Union

L 175/11

 

COMMISSION DIRECTIVE (EU) 2020/739

of 3 June 2020

amending Annex III to Directive 2000/54/EC of the European Parliament and of the Council as regards the inclusion of SARS-CoV-2 in the list of biological agents known to infect humans and amending Commission Directive (EU) 2019/1833

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Directive 2000/54/EC of the European Parliament and of the Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work (1), and in particular Article 19 thereof,

Whereas:

 

(1)

The Union strives to maintain its high standards for ensuring adequate protection of workers’ health, which is particularly relevant in the context of a global health pandemic. The outbreak of COVID-19, a new coronavirus disease, has affected all Member States since early 2020 and is causing major disruptions to all sectors and services, directly impacting the health and safety of all workers across the Union.

 

(2)

More than ever, strict compliance with and application of national provisions transposing Union rules on safety and health at work are of utmost importance. Directive 2000/54/EC lays down rules to protect workers against risks to their health and safety, including the prevention of such risks, arising or likely to arise from exposure to biological agents at work. It applies to activities in which workers are exposed, or are potentially exposed, to biological agents as a result of their work, and states the measures to be taken in the case of any activity likely to involve a risk of exposure to biological agents, to determine the nature, degree and duration of workers’ exposure to such agents.

 

(3)

Annex III to Directive 2000/54/EC sets out the list of biological agents known to infect humans, classified according to their level of risk of infection. In line with introductory note 6 in that Annex, that list should be amended to take into account the latest knowledge as regards scientific and epidemiological development that have brought about significant changes, including the existence of new biological agents.

 

(4)

In October 2019, Commission Directive (EU) 2019/1833 (2) amended Annex III to Directive 2000/54/EC, which resulted notably in the addition of a large number of biological agents, including the Severe Acute Respiratory Syndrome-related coronavirus (SARS-virus) and the Middle East Respiratory Syndrome coronavirus (MERS-virus).

 

(5)

The virus ‘severe acute respiratory syndrome coronavirus 2’ or, in short, ‘SARS-CoV-2’, which caused the outbreak of COVID-19, shows great similarities with the SARS-virus and the MERS-virus. Considering the epidemiological and clinical data currently available concerning the virus’ characteristics such as its transmission patterns, clinical features and risk factors for infection, SARS-CoV-2 should be added to Annex III to Directive 2000/54/EC as a matter of urgency, to ensure the continued adequate protection of workers’ health and safety at work.

 

(6)

SARS-CoV-2 can cause severe human disease among the infected population, presenting in particular a serious hazard to elderly workers and those with an underlying medical problem or chronic disease. While there is no vaccine or effective treatment currently available, considerable efforts are being deployed internationally and a significant number of vaccine candidates have so far been identified. Taking into account the latest scientific evidence and clinical data available as well as advice provided by experts representing all Member States, SARS-CoV-2 should therefore be classified as a risk group 3 human pathogen. Several Member States, as well as EFTA States and other...


More

This text has been adopted from EUR-Lex.

 

5.

Sources and disclaimer

For further information you may want to consult the following sources that have been used to compile this dossier:

This dossier is compiled each night drawing from aforementioned sources through automated processes. We have invested a great deal in optimising the programming underlying these processes. However, we cannot guarantee the sources we draw our information from nor the resulting dossier are without fault.

 

6.

Full version

This page is also available in a full version containing the legal context, de Europese rechtsgrond, other dossiers related to the dossier at hand and the related cases of the European Court of Justice.

The full version is available for registered users of the EU Monitor by ANP and PDC Informatie Architectuur.

7.

EU Monitor

The EU Monitor enables its users to keep track of the European process of lawmaking, focusing on the relevant dossiers. It automatically signals developments in your chosen topics of interest. Apologies to unregistered users, we can no longer add new users.This service will discontinue in the near future.